Galapagos NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Galapagos NV reports positive Phase 1 results for GLPG1205
Galapagos NV:Says that GLPG1205, a first-in-class molecule for inflammatory disorders, has demonstrated target engagement, a safety profile, and favorable drug properties in a Phase 1 study.Says Galapagos is developing GLPG1205 within its alliance with Janssen Pharmaceutica NV.Says aim of the Phase 1 study was to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral single and multiple ascending doses of GLPG1205.Says the randomized, double-blind, placebo-controlled, single center study was conducted in 40 healthy volunteers in Belgium.Says in the first part of the study, single ascending doses were evaluated and in the second part, the new compound was administered daily for 14 days.
Latest Developments for Galapagos NV
Latest Key Developments in Biotechnology
- Recro Pharma Inc announces full exercise of underwriters' option to purchase additional shares
- Rexahn Pharmaceuticals Inc announces initial results from phase I trial of SupinoxinTM (RX-5902) for solid cancer tumors
- Global Links Corp's subsidiary and Easton Pharmaceuticals Inc to Create Hemp-Based Product Line
- Tekmira Pharmaceuticals Corp announces proposed public offering of common stock
- Share this
- Digg this